University of Kentucky

UKnowledge
Epidemiology and Environmental Health Faculty
Publications

Epidemiology and Environmental Health

10-2016

Epigenetics of Lipid Phenotypes
Sergi Sayols-Baixeras
Universitat Pompeu Fabra, Spain

Marguerite R. Irvin
The University of Alabama at Birmingham

Donna K. Arnett
University of Kentucky, donna.arnett@uky.edu

Roberto Elosua
Institut Hospital del Mar d’Investigacions Mediques, Spain

Stella W. Aslibekyan
The University of Alabama at Birmingham

Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub
Part of the Cardiology Commons, Cardiovascular Diseases Commons, Epidemiology Commons, and
the Lipids Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Sayols-Baixeras, Sergi; Irvin, Marguerite R.; Arnett, Donna K.; Elosua, Roberto; and Aslibekyan, Stella W.,
"Epigenetics of Lipid Phenotypes" (2016). Epidemiology and Environmental Health Faculty Publications.
42.
https://uknowledge.uky.edu/epidemiology_facpub/42

This Article is brought to you for free and open access by the Epidemiology and Environmental Health at
UKnowledge. It has been accepted for inclusion in Epidemiology and Environmental Health Faculty Publications by
an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Epigenetics of Lipid Phenotypes
Digital Object Identifier (DOI)
https://doi.org/10.1007/s12170-016-0513-6

Notes/Citation Information
Published in Current Cardiovascular Risk Reports, v. 10, issue 10, article 31, p. 1-12.
© Springer Science+Business Media New York 2016
The copyright holder has granted the permission for posting the article here.
This is a post-peer-review, pre-copyedit version of an article published in Current Cardiovascular Risk
Reports. The final authenticated version is available online at: https://doi.org/10.1007/s12170-016-0513-6

This article is available at UKnowledge: https://uknowledge.uky.edu/epidemiology_facpub/42

HHS Public Access
Author manuscript
Author Manuscript

Curr Cardiovasc Risk Rep. Author manuscript; available in PMC 2017 October 01.
Published in final edited form as:
Curr Cardiovasc Risk Rep. 2016 October ; 10(10): . doi:10.1007/s12170-016-0513-6.

Epigenetics of Lipid Phenotypes
Sergi Sayols-Baixeras, MSc,
Cardiovascular Epidemiology and Genetics Group, Institut Hospital del Mar d’Investigacions
Mediques (IMIM), Dr. Aiguader, 88, Barcelona 08003, Spain, Universitat Pompeu Fabra (UPF),
Barcelona 08003, Spain, (tel) 34-93-316-07-27, (fax) 34-93-316-04-10

Author Manuscript

Marguerite R. Irvin, PhD,
Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB
220F, Birmingham, AL 35205, USA, (tel) 1-205-975-7672, (fax)1-205-975-3329
Donna K. Arnett, PhD,
College of Public Health, University of Kentucky, 111 Washington Avenue, Lexington, KY 40536,
USA, (tel) 1-859-257-5678, (fax) 1-859-257-8811
Roberto Elosua, MD, PhD, and
Cardiovascular Epidemiology and Genetics Group, Institut Hospital del Mar d’Investigacions
Mediques (IMIM), Dr. Aiguader, 88, Barcelona 08003, Spain, (tel) 34-93-316-08-00, (fax)
34-93-316-04-10

Author Manuscript

Stella W. Aslibekyan, PhD
Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB
230J, Birmingham, AL 35205, USA, (tel) 1-205-975-7675, (fax) 1-205-975-3329

Abstract
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Dyslipidemia is a well-established risk factor for cardiovascular disease, the main cause of death
worldwide. Blood lipid profiles are patterned by both genetic and environmental factors. In recent
years, epigenetics has emerged as a paradigm that unifies these influences. In this review, we have
summarized the latest evidence implicating epigenetic mechanisms—DNA methylation, histone
modification, and regulation by RNAs—in lipid homeostasis. Key findings have emerged in a
number of novel epigenetic loci located in biologically plausible genes (e.g. CPT1A, ABCG1,
SREBF1, and others), as well as microRNA-33a/b. Evidence from animal and cell culture models
suggests a complex interplay between different classes of epigenetic processes in the lipid-related
genomic regions. While epigenetic findings hold the potential to explain the interindividual
variability in lipid profiles as well as the underlying mechanisms, they have yet to be translated
into effective therapies for dyslipidemia.
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Elevated plasma triglycerides (TGs), alone or in conjunction with increased low-density
lipoprotein (LDL) and decreased high-density lipoprotein (HDL) cholesterol, are welldocumented risk factors for cardiovascular disease [1]. Despite high estimates of heritability
(48% and above [2]) and limited influence of shared environment, known genetic variants
explain approximately 10% of the observed variance in plasma lipids [3, 4]. Recent evidence
shows that a significant proportion of the remaining genetic variability may be attributable to
epigenetic processes, defined as heritable, non-sequence-dependent changes in gene
expression [5].

Author Manuscript

In contrast to sequence polymorphisms, epigenetic variation is specific, dynamic (and even
reversible throughout the lifecourse), and mechanistically diverse. These characteristics both
make it a lucrative target and pose translational challenges. For example, the cell and tissue
specificity enhances pathophysiologic relevance, but often complicates measurements as
probing some organs implicated in lipid metabolism—e.g. the liver—is invasive and costly.
While several studies have demonstrated conservation of epigenetic patterns and validated
the use of easily accessible tissues such as blood for epigenetic measurements [6], the
variants that remain tissue-specific are more likely to be causally related to disease risk.
Furthermore, the reversibility of epigenetic marks raises the issue of reverse causation: is the
change in the epigenetic profile a cause or a consequence of the phenotype? Despite
plausible mechanisms for either possibility in the lipid context, current evidence for DNA
methylation supports only the latter path, wherein lipids prime circulating immune cells to
regulate their own synthesis [7]. Finally, the sheer variety of biochemical modifications
involved in epigenetic inheritance creates a daunting yet promising ground for
investigations. Known processes that contribute to epigenetic effects are chromatin
remodeling via DNA methylation and histone modification, RNA-based mechanisms,
structural inheritance (or three-dimensional templating), and self-sustaining metabolic loops
(reviewed in [8]). Currently available evidence supports the diverse roles of DNA
methylation, histone modification, and regulatory RNAs in the setting of dyslipidemia; these
three classes of epigenetic mechanisms will constitute the main focus of this review.

DNA methylation
Author Manuscript

DNA methylation, which refers to the addition of a methyl group to the DNA molecule, is
by far the most studied epigenetic process with respect to human lipid traits, with several
large-scale epigenome-wide studies enabled by cost-effective methylation array technology.
In human somatic cells, DNA methylation occurs at approximately 70%–80% of cytosinephosphase-guanine (CpG) sites throughout the genome [9] and can be influenced by both
DNA sequence and environmental inputs. Depending on the location of the CpG site and the
physiologic context, methylation can down- or upregulate gene expression via a variety of
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mechanisms, including but not limited to effects on chromatin conformation, alternative
splicing, and mRNA transcript levels (reviewed in [10]).
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The emerging body of evidence linking lipids and DNA methylation includes three
categories: 1) cross-sectional studies fasting lipids; 2) epigenetic predictors or correlates of
lipid changes following a dietary or a pharmaceutical intervention; and 3) transgenerational
effects of maternal genotype and/or environment on offspring lipid levels. Fasting lipids are
a standard measurement in many epidemiologic cohorts and most early epigenetic studies
have focused on candidate gene or repetitive element methylation (Table 1). The most robust
and interesting targets, however, have arisen from epigenome-wide investigations of fasting
lipids (Table 2). The earliest such study reported two differentially methylated sites in
TNNT1 using the Illumina 27K technology in participants with familial
hypercholesterolemia [11]. However, these findings were not replicated in subsequent
studies using the higher-resolution Illumina 450K chip. Instead, the next wave of studies
pointed to methylation in the first intron of CPT1A, which encodes the liver isoform of
carnitine palmitoyltransferase 1 (CPT1), a key enzyme in the fatty acid biosynthesis pathway
[12]. A deficiency in CPT1 impairs the carnitine-dependent transport of long-chain fatty
acids into the mitochondria, lowering the rate of beta-oxidation [13] with profoundly
adverse metabolic effects [14]. In the first published epigenome-wide study of fasting lipids
using the 450K array, Irvin et al. have reported a robust inverse association between CPT1A
methylation and expression as well as fasting TGs and very low density lipoprotein (VLDL)
cholesterol [12]. Methylation at the top CPT1A locus explained 12% of TG variation in the
discovery cohort (Genetics of Lipid Lowering Drugs and Diet Network (GOLDN), CD4+
lymphocytes, n=991) and 6% in the replication cohort (Framingham Heart Study, whole
blood, n=1261) [12]. Subsequent studies have replicated the observed association with lipids
[7, 15, 16] and lipoprotein subfraction profiles [17], as well as linked CPT1A methylation
with obesity traits [18, 19], metabolic syndrome [20], and hypertriglyceridemic waist [21] in
diverse populations. Interestingly, CPT1A loci were also shown to be differentially
methylated in Dutch Hunger Winter survivors exposed to famine in utero, associating with
both birth weight and serum LDL cholesterol levels later in life [22] and providing a
possible mechanism for the well-known adverse metabolic sequelae of prenatal malnutrition.

Author Manuscript

Another robust association with multiple phenotypes, namely increased TGs and markers of
insulin resistance and decreased HDL-cholesterol, was reported in multiple cohorts and
tissues for a methylation locus in ABCG1 [15, 23]. Similarly to the CPT1A finding, the
observed association exhibits strong biological plausibility because the product of ABCG1
plays a central role in cholesterol and phospholipid reflux [24]. The differential methylation
pattern of ABCG1 with respect to HDL cholesterol and TGs, potentially mediated by
ABCG1 expression, was observed in both blood and adipose tissue but not skin, and
putatively associated with prevalent myocardial infarction [15]. The same epigenome-wide
study also identified and replicated associations between TGs and methylation loci in
MIR33B/SREBF1 and an intergenic region on chromosome 10, and between LDL
cholesterol and a locus in TNIP1 [15]. SREBF1, which contains intronic microRNA
(miR)33b, and SREBF2 encode transcription factors that regulate fatty acid and cholesterol
metabolism [25]. Notably, miR33b represses the transcription of both CPT1A and ABCG1
(reviewed in [15]), demonstrating the interplay between 1) genes that exhibit differential
Curr Cardiovasc Risk Rep. Author manuscript; available in PMC 2017 October 01.
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methylation in dyslipidemia and 2) various classes of epigenetic processes, in particular
methylation and RNA-based mechanisms. The first type of interplay is also illustrated by the
connection between the LDL-cholesterol locus in TNIP1, the gene encoding a protein that
interacts with tumor necrosis factor alpha, and ABCG1 via the peroxisome proliferatoractivated receptors (reviewed in [15]).
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Most reports of associations between methylation variants and lipid phenotypes in humans
came from cross-sectional studies, which preclude any inferences of temporality and thus
causality. The few dynamic studies of DNA methylation have yielded mixed results. In the
GOLDN cohort, there was no evidence that the changes in lipids that occur over the 3-week
long treatment with fenofibrate correlate with either epigenome-wide or candidate gene
methylation changes [26]. In the same study population, however, TG response to a high-fat
meal intervention was linked to differential methylation of CPT1A, APOA5, LPP, SREBF1,
and ABCG1 [unpublished], which collectively explained approximately 15% of the
phenotypic variance; however, the association was attenuated after adjustment for fasting
levels. Nevertheless, these epigenetic markers—three of which overlap with known
methylation correlates of fasting lipids— merit follow-up studies on the basis of their
functional plausibility. Other prospective evidence comes from transgenerational studies that
highlight the importance of the intrauterine environment for the risk of impaired metabolism
in the offspring [27, 28]. These studies, however, are few and limited by the lack of
mechanistic insights [28], repeated methylation measurements throughout the life course
[22], or both.

Author Manuscript
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The best evidence of causal relationships between lipids and DNA methylation comes from
a recent epigenomic study of lipids in whole blood from 3296 individuals that employed
stepwise Mendelian randomization, an instrumental variable approach which uses genotype
at a validated locus (e.g. a lipids genetic risk score) as a randomly assigned proxy for the
phenotype itself [7]. The advantages of Mendelian randomization, and particularly Egger
regression (MR-Egger) as implemented by Dekkers et al., include control for measured and
unmeasured confounding and pleiotropy [29]. Using the MR-Egger approach, this largest
epigenome-wide investigation of lipids to date has generated compelling evidence that lipids
influence differential methylation in CPT1A, SREBF1 (TGs), ABCG1 (TGs, HDL
cholesterol), and DHCR24 (LDL cholesterol), but not vice versa [7]. Of the four genes
causally implicated by MR-Egger, only DHCR24 had not been previously discussed in
cross-sectional studies. The DHCR24 gene is nevertheless highly relevant because it encodes
the enzyme catalyzing the terminal step in the cholesterol biosynthesis pathway [30], and is
regulated by sterol regulatory element binding proteins such as those encoded by SREBF1
[31]. The conclusions of the study, which support the causal effects of lipids on methylation
at several biologically plausible loci, are consistent with prior evidence of cholesterol
inhibiting its own synthesis—possibly via epigenetic priming that occurs prior to tissue
differentiation [32, 33, cited in 7]. Future studies would benefit from interrogating other
germane tissues, e.g. samples from adipose or hepatic biopsies, to identify a comprehensive
methylation signature for dyslipidemia. Finally, it is worth remarking that of all the genes
reported to present differential methylation associated with lipid traits, only some have been
identified in genome-wide association studies to be associated with these traits (e.g. CPT1A,
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MYLIP, and APOA5), highlighting the potential of epigenome-wide association studies to
explain the “missing heritability” of lipid metabolism [34, 35].

Histone modifications
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Post-translational modifications of diverse amino acid residues on histones, which include
acetylation, methylation, and phosphorylation, represent another class of epigenetic
mechanisms governing gene expression [36]. While chromatin immunoprecipitation (ChIP)
methods can be used to characterize histone modifications in selected regions (via
quantitative PCR) or on the epigenome-wide scale (via arrays or deep sequencing), most
existing studies of lipid phenotypes use this technology for follow-up of DNA sequence or
methylation findings rather than discovery. For example, functional annotation of 95 known
lipid SNPs [34] with data from the Encyclopedia of DNA Elements (ENCODE) project
found enrichment for histone marks associated with transcription regulation, particularly in
hepatic cells [37]. A similar analysis of SNPs in GALNT2, an HDL cholesterol locus, found
multiple instances of overlap with histone modification peaks in the liver [38]. This
approach may be especially promising in DNA methylation studies due to the cross-talk
between enzymes involved in both histone and DNA modifications [39]. The
interdependency of epigenetic processes is observed in all four genes harboring lipidregulated methylation loci, as the expression of DHCR24 [40], CPT1A [41], ABCG1 [42],
and SREBF isoforms [43] has previously been correlated with histone modifications in
human cells or animal models.
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In addition to functional studies of histone marks in known lipid loci, ChIP technology
offers the potential to identify novel epigenetic correlates of metabolic phenotypes, although
these studies are yet to be implemented on a large scale in humans. In Japanese macaques, in
utero exposure to a high-fat calorie-dense maternal diet has been shown to alter histone
acetylation patterns, putatively correlated with expression at several genes of interest, e.g.
Npas2 [44]. In humans, disrupted expression of circadian genes such as NPAS2 has been
extensively linked to abnormal metabolic phenotypes, specifically dyslipidemia (reviewed in
[45]), yet the underlying mechanisms are not well understood; epigenetic processes such as
post-translational histone acetylation warrant future studies as potential mediators.

Author Manuscript

Any discussion of histone modifications in the context of lipids would be remiss to exclude
statins, a broad class of drugs successfully used to lower LDL cholesterol levels by
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A). In addition to their
primary lipid-lowering action, statins also inhibit histone deacetylases (HDACs [46]),
notably HDAC2 in atherosclerotic plaques of human coronary arteries, and modulate
oxidized LDL-induced expression of inflammatory genes [47]. While these mechanistic
insights have generated enthusiasm, particularly in oncology [48], they have yet to be
translated into clinical breakthroughs.

RNA-based mechanisms
A number of non-coding RNAs, including small (<200 nucleotides) and long (≥200
nucleotides) non-coding RNAs, can indirectly regulate gene expression via interactions with
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canonical epigenetic processes such as histone acetylation/methylation or DNA methylation,
as well as directly by targeting mRNA [49]. The majority of research on their role in lipid
homeostasis to date has focused on microRNAs (miRNAs), which have been shown to
control lipoprotein levels in plasma (summarized in [50]) through several mechanisms. A
useful example is the well-studied miR-33a/b, previously discussed in the context of DNA
methylation findings. In experimental models, miR-33 isoforms decreased hepatic
biogenesis of HDL cholesterol and attenuated cellular cholesterol efflux in an ABCA1 and
ABCG1 dependent manner [51]. Additional evidence suggests that miR-33 inhibition
promotes regression of atherosclerotic plaques by affecting both lipid transport [52] and
inflammation [53]. Similar positive effects on plasma lipid profiles were achieved in
nonhuman primates [54], raising the therapeutic relevance of these discoveries. On the other
hand, miR-33 knockout mice fed a high-fat diet also exhibited increased total plasma
cholesterol, obesity, insulin resistance, and fatty liver, mediated by interactions with hepatic
SREBP-1 [25]. These deleterious metabolic effects, however, were not observed with
miR-33 inhibition rather than genetic deletion [55]. MiR-33 also has other targets, including
CPT1A and p53 (reviewed in [56]), although the current understanding of such disparate
effects is rather limited. The miR-33 story highlights the translational promise of small
regulatory RNAs in dyslipidemia and urges caution in regard to potential pleiotropic effects
of any miR-based therapies.

Author Manuscript

The role of long noncoding RNAs (lncRNAs) in lipid homeostasis is also coming to sharper
focus, with multiple in vitro studies implicating lncRNAs in hepatic lipid metabolism and
adipogenesis (reviewed in [57]). For example, a recent study identified LeXis (liverexpressed LXR-induced sequence), a lncRNA located in close proximity to Abca1 in the
murine genome, as a mediator of the liver X receptor-induced cholesterol efflux and
simultaneous decrease in cholesterol synthesis [58]. However, because lncRNAs are not as
highly evolutionarily conserved as miRNAs [57], the enthusiasm for their potential
therapeutic use must remain tempered until proof of concept from human studies. Overall,
RNA-based processes represent an important frontier in epigenetic studies of lipids, and
future large-scale human studies are poised to take advantage of shotgun transcriptomics
technologies (RNASeq) to further explore these mechanisms.

Conclusion

Author Manuscript

The epigenetic signature of dyslipidemia is complex, spanning multiple genomic regions,
biochemical processes, and phenotypes. The relationship between lipids and epigenetic
markers is dynamic and likely bidirectional; while lipid levels pattern methylation of key
relevant genes (CPT1A, ABCG1, SREBF1, DHCR24), other epigenetic processes (e.g.
regulation of gene expression by miR-33) are likely a cause rather than a consequence of
altered lipid profiles. The genomic regions implicated in dyslipidemia often harbor more
than one type of epigenetic change, as illustrated by the relationship between miR-33 and
methylation findings in ABCG1 and SREBF1, and epigenetic effects of each variant can be
pleiotropic. Future efforts aiming to realize the nontrivial translational potential of
epigenetic findings in dyslipidemia would benefit from heeding the intricate variability of
the observed patterns across time, tissue, and physiologic context.
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Table 1

Author Manuscript

Selected studies of candidate gene and repetitive element methylation and lipid phenotypes.
Repetitive Element Methylation Studies
Reference

Population (tissue)

N

Phenotype(s): associated changes in
global methylation

[59]

European (whole blood)

738

HDL-c: hypomethylation

[60]

European (whole blood)

228

TC, LDL-c, TG, HDL-c: hypomethylation

[61]

Samoan (whole blood)

355

LDL-c, HDL-c: hypomethylation

Candidate Gene Studies

Author Manuscript

Reference

Population (tissue)

N

Phenotype(s): associated gene

[62]

Canadian with severe obesity
(whole blood, adipose tissue)

73

LDL-c: LEP, ADIPOQ

[63]

Chinese children (whole blood)

98

LDL-c, TG, HDL-c: FAIM2

[64]

European American (CD4+ T
cells)

993

TC, LDL-c: APOE

[65]

European children with obesity
(whole blood)

85

TG: IGF2

[66], [67]

French Canadian with untreated
familial hypercholesterolemia
(whole blood)

98

LDL-c, HDL-c, TG: ABCG1, LIPC, PLTP
HDL-c: ABCA1

[68]

European American (whole
blood)

517

TC, LDL-c: FABP3

[69]

Chinese with diabetes and healthy
controls (peripheral blood
mononuclear cells)

47

TG: MCP1

[70]

Canadian women with severe
obesity (visceral adipose tissue)

92

HDL-c: DPP4
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Author Manuscript
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Table 2

Author Manuscript

Epigenome-wide studies of DNA methylation and lipid phenotypes.

Author Manuscript

Reference

Array

Population (tissue)

N

Phenotype(s): Top associated
CpG (gene)

[11]

Illumina 27K

French Canadian with
familial
hypercholesterolemia
(whole blood)

Discovery: 21
Replication: 70 (untreated) and
178 (treated with lipid-lowering
drugs)

HDL-c: cg07189381 (TNNT1)

[12]

Illumina 450K

European American
(CD4+ T cells)

Discovery: 663
Replication: 331

VLDL and LDL subfraction
parameters: cg00574958
(CPT1A)

[17]

Illumina 450K

European American
(CD4+ T cells)

Discovery: 991
Replication: 2711

VLDL-c and TG: cg00574958
(CPT1A)

[15]

Illumina 450K

European (whole
blood, adipose tissue,
skin)

Discovery (whole blood): 1776
Replication (whole blood): 971
Replication (adipose): 634
Replication (skin): 395

LDL-c: cg22178392 (TNIP1),
TG and HDL-c: cg06500161
(ABCG1)

[26]

Illumina 450K

European American
(CD4+ T cells)

443

Change in lipids following
fenofibrate treatment: no
significant findings

[22]

Reduced
Representation
Bisulfite
Sequencing

European, survivors of
the Dutch Hunger
Winter and sibling
controls (whole blood)

120

LDL-C: differentially
methylated region in CPT1A

[7]

Illumina 450K

European (whole
blood)

3296

LDL-c: cg27168858
(DHCR24), TG: cg11024682
(SREBF1), cg06500161/
cg27243685 (ABCG1) and
cg00574958/ cg17058475
(CPT1A), HDL-c: cg06500161/
cg27243685 (ABCG1)
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